詳細
Biological discovery is increasingly constrained by fragmented, costly, and narrowly focused analytical tools that limit scale and impact. This presentation highlights Illumina’s emerging multiomic and multimodal portfolio and its strategy to deliver a unified, scalable platform for biological insight. By integrating solutions across genomics, epigenomics, transcriptomics, proteomics, single‑cell, and emerging spatial modalities, Illumina removes traditional tradeoffs between depth, breadth, and throughput. Coupled with streamlined workflows and powerful data analysis across different data types and modalities, this approach enables researchers to rapidly interrogate complex genotype–phenotype relationships, stratify populations, and identify actionable biomarkers—accelerating translational discovery and enabling systems‑level understanding of biology and disease at scale.
Joel Fellis
Vice President & Distinguished Scientist, R&D
Illumina Inc.
Fill Out Form to Access Webinar
- 日時
- 2026/07/22
- Location
- Japan
- Asia
- Presenter
- Joel Fellis,
Vice President & Distinguished Scientist, R&D
Illumina Inc. - Topic
- Complex disease genomics